Anika Reports First Quarter 2024 Financial Results [Yahoo! Finance]
Anika Therapeutics Inc. (ANIK)
Last anika therapeutics inc. earnings: 2/20 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.anikatherapeutics.com/investor-relations
Company Research
Source: Yahoo! Finance
Cost reduction initiatives complete; On-track to achieve 2024 adjusted EBITDA guidance of $25-30 million, up over 75% at the midpoint BEDFORD, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today reported financial results for its first quarter ended March 31, 2024. First Quarter 2024 Financial Summary Revenue in the first quarter of 2024 was $40.5 million, up 7% compared to $37.9 million in the first quarter of 2023. OA Pain Management revenue of $24.3 million, up 7% Joint Preservation and Restoration revenue of $13.8 million, up 3% Non-Orthopedic revenue of $2.4 million, up 29% Gross margin was 61%; Adjusted gross margin was 62%. Net loss was ($4.5) million, or ($0.31) per share, compared to net loss of ($10.4) million, or ($0.71) per share, in the prior year period. Adjusted net income was $1.2 million, or $0.09 per diluted share, compared to adjusted net loss
Show less
Read more
Impact Snapshot
Event Time:
ANIK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANIK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANIK alerts
High impacting Anika Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
ANIK
News
- Pendopharm renews distribution agreement with Anika Therapeutics Inc. for Cingal®, Monovisc®, and Orthovisc® [Yahoo! Finance]Yahoo! Finance
- Anika Therapeutics, Inc. (NASDAQ: ANIK) had its "outperform" rating re-affirmed by analysts at Barrington Research. They now have a $37.00 price target on the stock.MarketBeat
- Hyaluronic Acid Market Surges to USD 18.75 Billion by 2031, Propelled by 8.7% CAGR - Verified Market Research® [Yahoo! Finance]Yahoo! Finance
- Anika Announces CFO Transition [Yahoo! Finance]Yahoo! Finance
- Anika Announces CFO TransitionGlobeNewswire
ANIK
Earnings
- 5/8/24 - Miss
ANIK
Sec Filings
- 5/8/24 - Form 10-Q
- 5/8/24 - Form 8-K
- 5/8/24 - Form 8-K
- ANIK's page on the SEC website